Quantcast
Home / News / Fosamax suit can’t proceed based on ‘sham’ issue

Fosamax suit can’t proceed based on ‘sham’ issue

Irreconcilable contradictions in expert testimony prevented a product liability plaintiff from establishing that Merck failed to provide adequate warnings with the osteoporosis drug Fosamax, the 2nd Circuit has ruled in affirming judgment.
Scroll To Top